These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 15709010)

  • 1. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.
    Tamura SI; Asanuma H; Ito Y; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Oya A
    Eur J Immunol; 1992 Feb; 22(2):477-81. PubMed ID: 1537382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.
    Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H
    J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
    Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
    Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
    Arulanandam BP; O'Toole M; Metzger DW
    J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.